Search

Two experiments were designed to investigate release patterns of oxytocin into plasma during oestrus and the early luteal phase. In Exp. 1, blood samples were collected from 5 ewes every 30 min for 10 h during 6 days around oestrus and the early luteal phase. During oestrus concentrations of oxytocin were generally low (1.27 +/- 0.54 pg/ml; mean +/- s.d.) but with occasional pulses up to 6 pg/ml. By Day 5 mean basal concentrations had risen to 4.5 +/- 2.1 pg/ml with a fluctuating release pattern. In Exp. 2, a method was developed for continuous blood sampling from conscious, unrestrained ewes. On the predicted day of oestrus following an untreated oestrous cycle, 8-ml blood samples were collected every minute for two 35-min periods (8 ewes: 16 sampling periods). For 6 ewes a ram was introduced to the pen for part of this time, and resulting behaviour was recorded. Additional blood samples were assayed for LH and progesterone to determine the stage of the cycle. Overall mean oxytocin concentrations ranged from 1.5 +/- 0.53 to 6.8 +/- 5.25 pg/ml in different animals. Ewes which were both in oestrus and exposed to the ram showed a pulsatile oxytocin release pattern consisting of low baseline concentrations with short-duration pulses superimposed (duration 1-4 min; amplitude 2.5-31.7 pg/ml; frequency 3.18/h). Coitus was not temporally associated with pulsatile release. However, the importance of the presence of the ram was indicated by total separation of 2 oestrous ewes from the ram until after experimentation. In these animals only 1 pulse of oxytocin was detected in 2.7 h of sampling. It is concluded that, although mean oxytocin concentrations at oestrus were low, short duration pulses were released into the plasma at this time. This effect may be dependent on the presence of a ram.

Anoestrous Romney Marsh ewes with or without progesterone pretreatment were injected with multiple low-doses of gonadotrophin-releasing hormone followed by a single, larger bolus. Blood samples were taken at twelve-hourly intervals for progesterone radioimmunoassay. Ewes were slaughtered on day 3 or 5 after the bolus injection, and the ovaries were collected for histology and immunocytochemical examination for oxytocin-immunocreactivity. The corpora lutea of all ewes killed on day 3 had similar weights and morphology. The ovaries of those ewes which were not pretreated with progesterone also contained some luteinized cysts. Ewes slaughtered on day 5 were separated into 2 groups according to plasma progesterone profiles, which were either rising (‘normal’), or falling after a transitory rise (‘abnormal’). Those ewes pretreated with progesterone all had a ‘normal’ progesterone profile whereas, of 14 ewes not pretreated with progesterone, 6 were ‘normal’ and 8 ‘abnormal’. Corpora lutea were significantly lighter in the ‘abnormal’ group and the ovaries of most of these ewes also contained luteinized cysts. All corpora lutea and luteinised cysts showed staining for oxytocin-immunoreactivity although the staining intensity was variable. In corpora lutea from ‘normal’ ewes oxytocin was restricted to large luteal cells. In addition tissues from ‘abnormal’ ewes also contained many cells with an atypical elongated shape which stained for oxytocin-immunoreactivity. These results show that progesterone pretreatment is needed for both normal morphological and endocrine development of corpora lutea in anoestrous ewes stimulated with gonadotrophin-releasing hormone.

In the pig, nest building occurs in the day preceding parturition (gestation=114--116 days). Nest building behaviour can be induced in pregnant, pseudopregnant and cyclic female pigs following injection of prostaglandin F2alpha. Here we investigated behaviour and endocrine changes after the administration of indomethacin, which inhibits cyclo-oxygenase enzymes and thus prostaglandin synthesis. In experiment 1, pregnant primiparous pigs (gilts) were blood sampled through jugular vein catheters every 20 min from 1000 h on day 113 of pregnancy and behaviour was recorded until birth. Two hours after pre-partum nest building began, animals received 4 mg/kg indomethacin (n=7) or control vehicle (n=8) intramuscularly. Indomethacin-treated animals showed less nest building than controls between 1 and 5 h after injection (P

The aim of this study was to show that the pig uterus synthesizes oxytocin. Uteri were obtained from 2-7 pigs at regular intervals during the oestrous cycle, throughout pregnancy, at parturition and in lactational anoestrus. Localization of mRNA encoding oxytocin was by in situ hybridization and oxytocin concentrations were measured by radioimmunoassay. As reproductive status changed, mRNA encoding oxytocin varied significantly (P < 0.05). Uterine tissue type was a significant factor in determining synthesis of mRNA encoding oxytocin (P < 0.001). In luminal epithelia, concentrations of mRNA encoding oxytocin were greater at oestrus than during day 14 of the luteal phase (P < 0.01) or at any stage of pregnancy (P < 0.05), with concentrations minimal at parturition. This trend was also exhibited in uterine circular muscle. In longitudinal muscle, concentrations of mRNA encoding oxytocin were lower during late pregnancy than at oestrus (P < 0.05) or during the luteal phase (P < 0.05). Concentrations were minimal at parturition. The oxytocin content in endometrial and myometrial tissue was positively correlated across reproductive status (P < 0.02, r = 0.402, n = 35). These data are the first indication that the uterine endometrium and musculature of the pig express mRNA encoding oxytocin. The luminal epithelium of animals at oestrus was particularly rich in mRNA encoding oxytocin, whilst late pregnant and parturient animals did not show a rise in mRNA encoding oxytocin. Local uterine synthesis of oxytocin may therefore be more important in control of the oestrous cycle than in pregnancy or at parturition in pigs.

In recent years there has been a burgeoning interest in the occurrence of the neurohypophysial hormones-oxytocin and vasopressin-outside the central nervous system. Much of this has focussed on the presence of the peptides in the gonads, and stems from the demonstration of significant amounts of oxytocin in the corpus luteum of the sheep ovary by Wathes and Swann (1982). This demonstration was followed rapidly by similar observations in other laboratories. Thus it was shown: that there was a higher concentration of oxytocin in the ovarian vein than in the corresponding artery of sheep in the luteal phase of the oestrous cycle (Flint and Sheldrick 1982); that the peptide was present in the bovine corpus luteum (Wathes et al. 1983); and that this probably represented the uterotonic substance 'contractin' that Fields et al. (1980) had extracted from bovine corpus luteum (Fields et al. 1983). Moreover, all of these studies brought to light observations which had been recorded at the beginning of the century. In their first description of the milk let-down effect of pituitary extracts, Ott and Scott (1910) showed that an aqueous extract of corpus luteum increased milk flow in the lactating goat, and this observation was confirmed using ovine corpus luteum in the lactating cat (Mackenzie 1911; Schafer and Mackenzie 1911). The discovery of oxytocin in the ruminant ovary, and the claims for its possible presence in the ovaries of other species, including man, raised the question of the possibility of its presence in the male gonad. So it was that an oxytocin-like peptide was sought and found in the testes of man and other species (Nicholson et al. 1984). The discovery of a biologically active molecule in a tissue raises a number of questions. In what cells of the tissue is the substance located and is it synthesized by them or accumulated by them? What is the chemical nature of the molecule; in the present case, is gonadal oxytocin identical with hypothalamic oxytocin? What is the physiological role of the molecule in that location? In the present paper we shall attempt to review the answers that have been provided to these questions so far, for both ovarian and testicular oxytocin. We have chosen to bias this article towards a review of the contributions from our laboratory in Bristol and thus say very little about the vasopressin-like peptides that also occur in the gonads. We attempt to direct the reader to work on such peptides by reference at the appropriate places, and further consideration can be found in the reviews by Clements and Funder (1986) and Wathes (1989), although the 'vasopressin' has not been studied as extensively as the oxytocin.

Oxytocin and the related peptide [Arg8]vasopressin (AVP) have previously been shown to bind with equally high affinity to oxytocin binding-sites (presumed oxytocin receptors) present within the uterus and oviduct of oestrous ewes. There is a possibility, therefore, that AVP mediates oxytocic actions through these binding sites. For the present study, ewes in seasonal anoestrus were treated with oestradiol-17 beta (50 micrograms subcutaneously, daily for 2-4 days). It was shown initially that this treatment stimulated the development of high-affinity oxytocin binding-sites (Kd 4.4 +/- 0.8 nmol L-1) which had similar affinity for AVP (Kd 4.2 +/- 0.9 nmol L-1) in the myometrium. The efficacy of oxytocin and AVP in vivo were compared by recording electromyographic (EMG) activity from the ampullary-isthmic junction of the left oviduct and the left uterine horn of four conscious ewes. Before oestradiol treatment there was no EMG response to oxytocin even at supraphysiological (1000 mU) doses. During oestradiol treatment, EMG activity was consistently increased in response to injections of 25 mU and 100 mU oxytocin via the jugular vein, but not to saline or 100 mU AVP. Higher doses of AVP were not investigated because of the possibility of cardiovascular side effects. A subsequent blood sampling experiment showed that maximal concentrations of oxytocin and AVP (achieved in peripheral plasma during the first 2 min following injection into the jugular vein) were of a similar order of magnitude after injection of equivalent doses of the two peptides. It is concluded that AVP probably does not mediate biological activity through the oxytocin receptor in non-pregnant ewes.(ABSTRACT TRUNCATED AT 250 WORDS)

This study tested the hypothesis that the administration of oxytocin in doses equivalent to endogenous concentrations at and around oestrus could affect uterine and oviductal muscular activity at the time of gamete transport. Four ewes were fitted with recording electrodes in the left ampulla, ampullary-isthmic junction, utero-tubal junction and uterine horn. After surgical recovery, recordings from conscious free-standing animals were made for up to 10 h per day from Day -3 to Day +3 relative to oestrus in each ewe. Daily blood samples were taken for progesterone radioimmunoassay, and a vasectomized ram used to assess oestrus. A range of physiological doses of oxytocin (10-100 mU), or control saline injections were given intravenously. Electromyographic (EMG) activity was measured before and after injections. Spontaneous activity throughout the reproductive tract was low on Day -3 but increased to peak at oestrus (P < 0.05), when the pattern of activity consisted of short (2-10 s) co-ordinated high amplitude bursts (2-5 min-1). After oestrus, as overall activity declined, longer episodes of activity appeared but these occurred with a much slower frequency (1-4 h-1). Responsiveness to oxytocin was greatest on the day of oestrus at all electrode sites. Elevated responsiveness (relative to Day -3, the late luteal phase) was seen from Day -1 to Day +2 at the ampullary-isthmic junction and uterus, but on the day of oestrus only at the ampulla and utero-tubal junction. Duration of increased EMG activity after oxytocin injection ranged from 5 to 20 min. These results show for the first time that the uterine and oviductal musculatures of the ewe in vivo reached a peak in sensitivity to physiological concentrations of oxytocin at oestrus. When combined with information on oxytocin receptor populations and endogenous circulating concentrations, this suggest that endogenous oxytocin could influence oviduct and myometrial activity at this time.

Anoestrous Romney Marsh ewes with (+P) and without (-P) progesterone pretreatment were induced to ovulate by multiple low-dose injection of GnRH followed by a bolus injection of GnRH. Luteal function was assessed by twice daily measurement of plasma progesterone. Animals were slaughtered on Days 3 or 5 after the end of GnRH treatment and CL and endometrium were recovered. In all Day-5 ewes, blood samples were collected at 30-min intervals for 8 h on Days 3 and 5 for measurement of PGFM and oxytocin. At slaughter 92% of the Group +P ewes had ovulated compared with 54% of the Group -P ewes. The ovaries of some of the Group -P ewes only contained luteinized cysts either alone or in association with CL. In the ewes that ovulated, progesterone profiles were normal in all Group +P ewes, whereas Group -P ewes had 'normal' or 'abnormal' profiles in which plasma progesterone was declining prematurely. All of the CL from ewes with abnormal progesterone profiles were associated with follicular cysts, and were significantly smaller and with a lower progesterone content on Day 5. PGFM levels decreased (P less than 0.05) between Days 3 and 5 in ewes in Groups +P and -P with 'normal' CL but increased (P less than 0.01) in Group -P ewes with 'abnormal' CL. Oxytocin levels were lower in Group -P ewes with 'abnormal' CL on Day 5, than in 'normal' ewes in Groups -P (P less than 0.01) or +P (P less than 0.05). In 3/5 Day-5 ewes with 'abnormal' CL there was a clear association between a major peak of oxytocin and a rise in PGFM during the frequent sampling period on Day 3 or Day 5, and endometrial oxytocin binding sites were present at slaughter. This suggests that the premature regression of 'abnormal' CL occurs via the normal luteolytic mechanism. Although ewes in Groups +P and -P with 'normal' CL had similar progesterone profiles, plasma oxytocin was significantly higher (P less than 0.05) in the Group -P ewes and oxytocin binding sites were present only in this group, suggesting that progesterone pretreatment can influence the production of both oxytocin and its receptor.

Oestrus was synchronized in 8 cyclic heifers by progesterone treatment (PRID), after which the animals were monitored for one control cycle to measure the inter-oestrous interval. Osmotic minipumps containing saline (controls, N = 3) or oxytocin (N = 5) were implanted subcutaneously on Day 10 of the second cycle, and removed 12 days later. Jugular venous blood samples were collected daily for measurement of progesterone, and every 2 days for oxytocin. In addition, blood samples were taken every 10 min from 1 h before to 3 h after minipump insertion for measurement of plasma 15-keto-13,14-dihydroprostaglandin-F-2 alpha (PGFM) and every 30 min over the same period for measurement of progesterone and oxytocin. The lengths of the first untreated cycle in both groups of heifers were 20.2 +/- 0.56 (mean +/- s.e.m.) days compared with 25.4 +/- 0.81 days after oxytocin treatment (P less than 0.001). Oxytocin plasma concentrations in treated animals rose from less than 10 pg/ml to 70-500 pg/ml by 2 h after the start of oxytocin infusion and remained elevated until treatment was withdrawn. There was no increase in PGFM concentrations immediately after minipump insertion. Plasma progesterone concentrations were similar in treated and control animals but remained at mid-luteal levels for an average of 5 days longer in treated heifers. It is concluded that continuous administration of oxytocin can extend the luteal life-span in cattle.